Navigation Links
Chinese SFDA Grants Immtech Fast Track Status
Date:9/27/2007

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Immtech) (Amex: IMM) announced today that the State Food and Drug Administration of the People's Republic of China (SFDA) has granted Immtech's application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company's oral drug candidate for the treatment of Pneumocystis pneumonia (PCP). Pafuramidine is among the first drugs to be considered for Fast Track Status under new and more stringent SFDA rules recently introduced in China. The PCP clinical trial to be conducted in China will be under the US FDA protocol (http://www.sfda.gov.cn).

Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech stated, "This is a significant milestone for Immtech to work in China to accelerate the approval and availability of pafuramidine as a treatment for PCP. As the most populous nation in the world, China is well positioned to support and benefit from important efforts to combat PCP and other devastating infectious diseases."

PCP is a fungal infection in the lungs and can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. An estimated one million adults and children are afflicted with PCP worldwide, and approximately five million more receive prophylaxis.

PCP is one of the most common opportunistic infections in the estimated 42 million AIDS/HIV patients worldwide. There are only a few treatment options for PCP, and patient intolerance of current therapies is a significant problem. In addition, molecular evidence suggests that resistance of Pneumocystis fungus to current therapy is increasing and may result in failure of treatment or prophylaxis. Pending approval to proceed by the Chinese regulatory authority, pafuramidine will be the first drug candidate to advance to clinical stage development in China for HIV related PCP.

Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer, stated, "We are enthusiastic about the opportunity to conduct clinical trials in China. International collaboration will be an essential element in global efforts to treat infectious diseases, and we look forward to working closely with China's Centers for Disease Control and other health organizations to bring safe and effective drugs to market."

In June 2007, Immtech entered into an exclusive licensing agreement with Par Pharmaceutical Companies, Inc. (NYSE: PRX) under which Par will receive commercialization rights in the U.S. to pafuramidine for the treatment of PCP in AIDS patients.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit http://www.immtechpharma.com.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward- looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
2. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
5. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
6. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
7. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):